Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 2, 2013, Pages 284-293

  Dey, Teesta ^a   Brigden, Grania ^b   Cox, Helen ^b,c   Shubber, Zara ^a   Cooke, Graham ^a,d   Ford, Nathan ^b,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Multidrug resistant tuberculosis; Repurposed drugs; Treatment success

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; TERIZIDONE;

ABDOMINAL PAIN; ARTICLE; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; NAUSEA AND VOMITING; SHORT COURSE THERAPY; SIDE EFFECT; SKIN PIGMENTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84872371975     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks389     Document Type: Article

References (39)

1. Keshavjee S, Farmer P. Picking up the pace-scale-up of MDR tuberculosis treatment programs. N Engl J Med 2010; 363: 1781-4.
2. WHO. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: WHO, 2011.
3. Lienhardt C, Raviglione M, Spigelman M et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205 Suppl 2: S241-9.
4. WHO. 2011/2012 Tuberculosis Global Facts. 2011. www.who.int/tb/ publications/2011/factsheet_tb_2011.pdf (29 August 2012, date last accessed).
5. Orenstein E, Basu S, Shah N et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-61.
6. Rao N, Irfan M, Mahfooz Z. Treatment outcome of multi-drug resistant tuberculosis in a tertiary care hospital in Karachi. JPMA 2009; 59: 694-8.
7. Olle-Goig JE, Sandy R. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. Int J TB Lung Disease 2005; 9: 765-70.
8. Collin B, duCros P, Ford N et al. Treating Drug-Resistant TB: What Does it Take? London: Médecins Sans Frontie' res, 2011.
9. Nzila A, Ma Z, Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem 2011; 3: 1413-26.
10. Cholo M, Steel H, Fourie P et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-8.
11. Telles M, Chimara E, Ferrazoli L et al. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005; 54: 975-9.
12. Garrelts J. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP 1991; 25: 525-31.
13. Gangadharam P, Perumal V, Podapati N et al. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-3.
14. Shen G, Wu B, Hu S et al. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35: 400-4.
15. Reddy V, O'Sullivan J, Gangadharam P. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43: 615-23.
16. Jagannath C, Reddy M, Kailasam S et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Resp Crit Care Med 1995; 151: 1083-6.
17. Van Deun A, Maug A, Salim M et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Resp Crit Care Med 2010; 182: 684-92.
18. Moher D, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
19. Wells G. The Newcastle Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analysis. In: Proceedings of the Third Symposium on Systematic Reviews. Beyond the Basics: Improving Quality and Impact, Oxford, 2000.
20. Bonnet M, Pardini M, Meacci F et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PloS One 2011; 6: e23081.
21. Goble M, Iseman M, Madsen L et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-32.
22. Senaratne W. Outcome of treatment of multidrug resistant tuberculosis. Ceylon Med J 2004; 49: 86-7.
23. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006; 52: 92-6.
24. Xu H, Jiang R, Tang S et al. Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment. J Antimicrob Chemother 2012; Epub ahead of print 5 March 2012 doi:10.1093/jac/dks077.
25. Mitnick C, Shin S, Seung K et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-74.
26. Dalcolmo M, Borga L, Cardoso N et al. Outcomes of MDR-TB diagnosis and treatment using a standardized regimen during a 5-year period in Brazil. In: The Thirty-seventh World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, 2006. p. S184.
27. Prasad M, Shashirekha K, Bhattacharyya D et al. Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases. In: The ERS Annual Congress (Session 252-The Challenge of Multidrug-Resistant Tuberculosis), Berlin, 2008. p. 441s.
28. Prasad M, Rai S, Falleiro J et al. Prevalence and treatment outcome of drug resistant pulmonary tuberculosis in HIV negative cases-experience from tuberculosis treatment center in India. In: The ERS Annual Congress (Session 400-Multi/Extensively-Drug Resistant Tuberculosis), Vienna, 2009. p. 786s.
29. Oliveira M. Profile of patients with failure to the treatment of MDR-TB in the State of Sao Paulo from 1999-2004. In: The Thirty-eighth World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Cape Town, South Africa, 2007. pp. S290-S1.
30. Piubello A, Harouna S, Boukary I et al. Resultats d'un traitement standardisé de courte durée de la tuberculose multirésistante au Niger. In: The Forty-second World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union), Lille, France, 2011. pp. S108-S9.
31. Johnston J, Shahidi N, Sadatsafavi M et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and metaanalysis. PLoS One 2009; 4: e6914.
32. Moszynski P. WHO launches plan to fight drug resistant tuberculosis. BMJ 2007; 334: 1340-1.
33. Chaisson R, Keiser P, Pierce M et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-7.
34. WHO. WHO Model Prescribing Information: Drugs Used in Mycobacterial Diseases. 1991. http://apps.who.int/medicinedocs/es/d/ Js5511e/3.1.html (29 August 2012, date last accessed).
35. Anon. DR-TB Drugs Under the Microscope. Geneva: Médecins Sans Frontie'res, 2011.
36. Mitnick C, Horsburgh C. Encouraging news for multidrug-resistant tuberculosis treatment. Am J Resp Crit Care Med 2010; 182: 1337-8.
37. WHO. "Totally Drug-Resistant TB": a WHO Consultation on the Diagnostic Definition and Treatment Options. 2012. http://www.who.int/tb/challenges/xdr/Report_Meeting_totallydrugresistantTB_032012.pdf (29 August 2012, date last accessed).
38. Tomlinson C. Clofazamine. http://www.tbonline.info/posts/2011/8/24/clofazamine/ (29 August 2012, date last accessed).
39. Caminero J, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.